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Abstract 1 
Objective To compare the duration, quality of anaesthesia and analgesia and quality of 2 
recovery of dexmedetomidine and methadone combined with either ketamine or 3 
alfaxalone.  4 
Study design Randomized prospective clinical trial.  5 
Animals Forty-four healthy client-owned cats presenting for ovariectomy.  6 
Methods Cats were randomly assigned to one of two treatment groups: DAM (n=22), 7 
which were administered intramuscular (IM) dexmedetomidine (15 µg kg-1), methadone 8 
(0.3 mg kg-1) and alfaxalone (3 mg kg-1), and DKM (n=22), which were administered 9 
IM dexmedetomidine (15 µg kg-1), methadone (0.3 mg kg-1) and ketamine (3 mg kg-1). 10 
During anaesthesia, heart rate, respiratory rate and systolic arterial pressure were 11 
measured every 5 minutes. Cats that moved or had poor muscle relaxation were 12 
administered an additional 1 mg kg-1 intravenously (IV) of either alfaxalone (DAM) or 13 
ketamine (DKM). In cases of increased autonomic responses to surgical stimulation, 14 
fentanyl (2 µg kg-1) was administered IV. At the end of the surgery, atipamezole (75 µg 15 
kg-1) was administered intramuscularly and the times to both sternal recumbency and 16 
active interaction were recorded. Quality of recovery was evaluated with a Simple 17 
Descriptive Scale. The UNESP-Botucatu multidimensional composite pain scale and a 18 
Visual Analogue Scale (VAS) were used to evaluate post-operative analgesia at the 19 
return of active interaction and 1, 2 and 3 hours later.  20 
Results The additional anaesthesia and rescue fentanyl requirements were similar 21 
between groups. The quality of recovery was better in the DAM group than the DKM 22 
group (SDS scores: 0[0-1] and 1[0-3], respectively; p = 0.002). Postoperative pain 23 
scores decreased progressively over time in both groups with no significant differences 24 
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(p = 0.08) between them.  25 
Conclusions and clinical relevance Both protocols provided comparable quality of 26 
anaesthesia and analgesia that were suitable for cats undergoing ovariectomy. In 27 
combination with methadone and dexmedetomidine, alfaxalone and ketamine showed 28 
comfortable and reliable recoveries. 29 
 30 
Introduction 31 
Ovariectomy is one of the most common reasons for anaesthesia in young female cats in 32 
Europe. Due to the fractious nature of some cats and the limited anaesthesia equipment 33 
availability of many small veterinary clinics, an intramuscular (IM) anaesthetic protocol 34 
offers distinct advantages. However, the anaesthetic drugs should be safe, well-absorbed 35 
by IM route and provide reliable unconsciousness, muscle relaxation and analgesia.  36 
In cats, alpha-2 agonists are commonly used anaesthetic agents because they 37 
provide reliable sedation and short-term analgesia (Cullen et al. 1996; Murrell et al. 38 
2005; Nagore et al. 2013). Furthermore, opioid and alpha-2 agonist combinations have a 39 
synergistic analgesic effect (Meert et al. 1994; Slingsby et al. 2014) and provide deeper 40 
sedation compared with the effect of either agent alone (Girard et al. 2010). 41 
Ketamine is often used in combination with opioids and alpha-2 agonists 42 
because it is inexpensive and offers the advantage of producing predictable dissociative 43 
and analgesic effects (Ko et al. 2011; Harrison et al. 2011; Carbone 2012). However, 44 
repeated dosing of ketamine during anaesthesia has been associated with drug 45 
accumulation and delayed recovery in cats (Baggot et al. 1976; Liu et al. 2006). 46 
Furthermore, ketamine stimulates the cardiovascular system (increase heart rate (HR), 47 
blood pressure and cardiac output) because of central stimulation of the sympathetic 48 
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system. This leads to an increase in myocardial work that increases the myocardial 49 
oxygen demand leading to impaired cardiovascular function in cats with underlying 50 
cardiac disease (Clutton 2007). This effect potentially endangers fractious cats in which 51 
preanaesthetic examination is not feasible. 52 
Alfaxalone is a neurosteroid anaesthetic available in Europe in a cyclodextrin 53 
based formulation (Alfaxan, Jurox, Australia). It has excellent cardiovascular stability 54 
(Muir et al. 2009) and fast clearance from the body, making it suitable for repeated 55 
dosing during anaesthesia (Whittem et al. 2008). Consequently, alfaxalone offers some 56 
advantages over ketamine when it is used as part of a balanced anaesthetic protocol. 57 
Alfaxalone has been used at different dosages to induce anaesthesia intravenously (IV) 58 
(Pinelas et al. 2014) and IM (Grubb et al. 2013). Alfaxalone may have analgesic 59 
properties, resulting from its blockade of T-type Ca2+ channels and potentiation of 60 
GABAA ligand-gated channels (Pathirathna et al. 2005). However, a beneficial 61 
analgesic benefit has not been observed clinically (Winter et al. 2003; Murison & 62 
Martinez Taboada 2010). 63 
The aim of this study was to compare the anaesthetic, cardiorespiratory, 64 
analgesic and recovery quality effects of ketamine or alfaxalone in combination with an 65 
alpha-2 agonist (dexmedetomidine) and an opioid (methadone), in cats undergoing 66 
ovariectomy.  67 
Materials and methods 68 
The study was approved according to Directive 2010/63/EU by the Chair of the 69 
Veterinary University Hospital Ethics Approval Board and informed consent was 70 
obtained from all owners. 71 
 72 
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Animals 73 
The sample size was calculated using a commercial software program (SigmStat and 74 
SigmaPlot 12) to detect a Visual Analogue Scale (VAS) difference between groups of 75 
10 mm with a standard deviation of xx using a T-test with 80% power and 5% 76 
significance.  77 
Forty-nine clients owned female cats undergoing elective ovariectomy were included in 78 
the study (Fig. 1). Cats underwent routine preanaesthetic physical examination in order 79 
to assess their health status according to the American Society of Anesthesiologists 80 
(ASA) classification. Exclusion criteria were ASA ≥ II, fractious personality and age 81 
greater than eight years. 82 
 83 
Anaesthesia and surgery 84 
The cats were fasted by the owners for 12 hours before being admitted to the university 85 
hospital of Veterinary Medicine of Alfort, France, on the scheduled surgery day.  On 86 
arrival, a preanaesthetic physical examination was performed.  Study-eligible cats were 87 
then individually housed in single cages in a dedicated cat room and were randomly 88 
assigned, based on drawing numbered pieces of paper from an envelope, to one of two 89 
treatment groups.  Group DAM (n=22) were administered IM dexmedetomidine (15 µg 90 
kg-1; Dexdomitor; Orion Pharma, Finland), methadone (0.3 mg kg-1; Comfortan; 91 
Eurovet, Belgium) and alfaxalone (3 mg kg-1; Alfaxan;, Jurox, Australia) and Group 92 
DKM (n=22) were administered IM dexmedetomidine (15 µg kg-1), methadone, (0.3 mg 93 
kg-1) and ketamine (3 mg kg-1 Imalgene 1000; Mérial, France). 94 
All cats were injected IM with one of the two anaesthetic combinations prepared 95 
by a veterinarian not directly involved in the study. This individual also equalized the 96 
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volume of the DKM solution to that of the DAM solution using sterile saline so the 97 
anaesthetist could not discern which treatment combination was being administered. 98 
When the injection volume exceeded 1 mL, the anaesthetic combination was 99 
administered into two injection sites (right and left lumbar muscles). Times to sternal 100 
and lateral recumbency, quality of induction and adverse effects such as vomiting, 101 
hypersalivation, distress, tremors, myoclonus and increased muscle tone were recorded. 102 
Sternal recumbency was defined as a position in which the legs were tucked under the 103 
body and the cat has a decreased responsiveness to its surroundings. Lateral 104 
recumbency was defined as a position in which the cat lay on its side and was 105 
unresponsive to its surroundings. General anaesthesia was considered induced when the 106 
cats were shifted from lateral to dorsal recumbency, and did not attempt to reposition 107 
themselves. If general anaesthesia was not induced within 30 minutes after the injection, 108 
the cats were reinjected IM  with half of the initial doses of both dexmedetomidine and 109 
alfaxalone for the DAM group, or dexmedetomidine and ketamine for the DKM group, 110 
without methadone and were excluded from the study. Once anaesthesia was induced, a 111 
22-gauge catheter (Delta Med, Italy) was placed in the cephalic vein. All cats were then 112 
administered 7 mL kg-1 hour-1 of sterile saline (NaCl 0.9%, B. Braun, Germany) IV 113 
during the procedure. 114 
An IV injection of 20 mg kg-1 of amoxicillin (Clamoxyl, GlaxoSmithKline, UK) 115 
was administered as soon as the catheter was placed, and then repeated at the end of the 116 
surgery. Eye lubricant (Ocrygel; TVM, France) was applied at the beginning of 117 
anaesthesia and then every 45 minutes until recovery. For the surgery, cats were 118 
positioned in dorsal recumbency. Time from the beginning (first incision of the 119 
abdominal wall, coeliotomy) to the end of surgery (last suture knot) was recorded. 120 
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Surgeries were performed by final year veterinary students under the direct supervision 121 
of in-house surgeons. A multiparametric monitor (Cardiocap II, Datex, IL, USA) was 122 
used during anaesthesia. Heart rate and rhythm were monitored by electrocardiography, 123 
respiratory rate (fR) was assessed by visual observation of chest movements, pulse rate 124 
and arterial oxygen saturation (SpO2) were detected by pulse oximetry, and systolic 125 
arterial pressure (SAP) was intermittently measured using a Doppler (Doppler Vet BP; 126 
Sonomed, Poland) placed over the ulnar artery. The animals were allowed to breathe 127 
room air. Cats showing signs of hypoventilation (fR < 6 breaths minute-1) or severe 128 
hypoxemia (SpO2 < 90%) were intubated, manually ventilated and excluded from the 129 
study. Animals with arterial saturation values less than 94% SpO2, were supplemented 130 
with oxygen (FIO2 100%) at a rate of 2 L minute-1 via a mask. In the event that oxygen 131 
supplementation did not result in normalization of SpO2, the cats were intubated to 132 
permit manually assisted ventilation with 100% oxygen and excluded from the study. 133 
Animals were maintained at a body temperature above 36.5° C by a forced air warmer 134 
(Warm Touch; Mallinckrodt Medical, Ireland). 135 
During surgery the depth of anaesthesia was evaluated every 5 minutes, based 136 
on the following descriptors: occurrence of spontaneous blinking (yes/no), occurrence 137 
of movements during surgical stimulation (yes/no), and inadequate muscle relaxation 138 
(yes/no). If two of the above parameters were observed (i.e. yes) then the patient 139 
received either alfaxalone 1 mg kg-1 IV (DAM) or ketamine 1 mg kg-1 IV (DKM). 140 
 141 
Intraoperative nociceptive evaluation 142 
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For each cat, baseline values for HR, fR and SAP were determined prior to surgical 143 
stimulation. When two of these three parameters increased by 30% above the baseline, 2 144 
µg kg-1 fentanyl (Fentanyl; Mylan, France 50 µg ml-1) was administered IV.  145 
Postoperative pain assessment and quality of recovery assessment 146 
At the end of the surgery (defined as time of tying last suture knot), but not earlier than 147 
30 minutes after the last anaesthetic (ketamine or alfaxalone) supplemental dose, all 148 
animals received atipamezole 75 µg kg-1 IM (Alzane, Zoetis, NJ, USA). Time to sternal 149 
recumbency and active interaction (defined as responsiveness to voices, alertness and 150 
interest in the surroundings) were recorded. Quality of recovery was evaluated after 151 
atipamezole injection until the cat regained sternal recumbency.  A simple descriptive 152 
scale (SDS) indicated by (0) very smooth recovery, (1) smooth recovery, (2) poor 153 
recovery and (3) very poor recovery requiring rescue sedation (dexmedetomidine, 2 µg 154 
kg-1 IV), was used. 155 
Postoperative pain was evaluated, at the same time points, using two different 156 
scoring systems. Firstly, a modified version of the UNESP-Botucatu multidimensional 157 
composite pain scale (MCPS) (Brondani et al. 2013), where the maximum total score 158 
was 24 instead of 30, because of the exclusion of the subscale “physiological change”, 159 
which was incompatible with the drug used in our study.  Secondly, a Visual Analogue 160 
Scale (VAS) was used where 0 mm was labelled as “no pain” and 100 mm as “worst 161 
possible pain” (Jensen et al. 2003). The same anaesthetist performed the pain 162 
assessments starting at the first spontaneous cat interaction (T0), and then at 1 (T1), 2 163 
(T2) and 3 (T3) hours later. Buprenorphine (Vetergesic; Sogeval, France) 20 µg kg-1 IV 164 
was administered as postoperative rescue analgesia when a score greater than “two” for 165 
the subscale “expression of pain”, or a score greater than “three” for the subscale 166 
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“psychomotor changes” was recorded on the UNESP-Botucatu MCPS, and/or when the 167 
VAS score exceeded  40 mm of the maximum value of 100 mm. At the end of the pain 168 
assessment, all cats were administered 0.2 mg kg-1 meloxicam (Metacam; Boehringer-169 
Ingelheim, Germany) subcutaneous (SC) and 20 µg kg-1 buprenorphine SC, unless 170 
buprenorphine had been administered earlier as postoperative rescue analgesia. The 171 
same anaesthetist evaluated intraoperative nociception, all assessments of postoperative 172 
pain and quality of recovery.  173 
 174 
Statistical analysis 175 
Descriptive statistics were performed to assess the normal distribution of data. To 176 
compare the intraoperative physiological variables (HR, fR and SAP) between the two 177 
treatment groups, a repeated measures ANOVA (A) followed by a Bonferroni multiple 178 
comparison test were used. The time for the first supplemental bolus and the duration of 179 
surgery followed a normal distribution. For this reason, a t-test (T) was used. To 180 
compare the total dose of intraoperative rescue fentanyl, postoperative rescue 181 
buprenorphine and rescue sedation by each group, a Fisher’s test (F) was used. Total 182 
dose of alfaxalone or ketamine administered to each group, time to active interaction 183 
and SDS scores for assessment of recovery quality were analysed with non-parametric 184 
tests. For this reason, a Mann-Whitney test was used (MW). The composite pain, 185 
UNESP-Botucatu MCPS and VAS scores achieved by each group over time were 186 
analysed by repeated measures ANOVA followed by a Bonferroni multiple comparison 187 
test. 188 
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Statistical analysis was performed using commercially available software 189 
(NCSS, 2007; SigmaPlot 12). Values of p < 0.05 were considered significant. Data are 190 
reported as mean ± standard deviation or median (range).  191 
 192 
Results 193 
Animals 194 
Data were normally distributed only for the duration of anaesthesia and the time to 195 
anaesthetic induction. Five cats were excluded because of their fractious nature (Fig. 1). 196 
The remaining 44 animals were classified as ASA I, and none were rejected after 197 
preanaesthetic physical examination.  These 44 cats were randomly allocated to the two 198 
anaesthetic combination groups. The treatment groups did not differ statistically with 199 
respect to age [7 (6-74) months] and body weight [2.8 (1.8-4.1) kg]. Anaesthetic 200 
induction was smooth in all animals, additional doses were not required to achieve a 201 
surgical plane of anaesthesia, and apnoea, vomiting or emergence reactions were not 202 
observedn. The average time from IM injection to sternal recumbency and the time to 203 
sternal and lateral recumbency are summarized in Table 1. 204 
 205 
Anaesthesia and intraoperative nociceptive evaluation 206 
The duration of surgery was 75 ± 16 minutes for DAM and 69 ± 15 minutes for DKM 207 
(p = 0.22T). Time to the first supplemental dose after the initial IM injection was 208 
different between groups (p = 0.046T) (Table 1). There was no difference (p = 0.44MW) 209 
between groups in the number of alfaxalone doses administered during surgery (Table 210 
1). 211 
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There was no difference in HR (p = 0.23A) and SpO2 (p = 0.26A) between groups 212 
(Table 1). None of the animals required endotracheal intubation, but 18 cats, nine from 213 
each group, were administered 100% oxygen supplementation by mask. In these 214 
animals, SpO2 increased to values higher than 94% after a few minutes, at which point 215 
the oxygen was disconnected and additional oxygen supplementation was not required 216 
again during the study.  217 
 The fR was higher in DAM compared with DKM (p = 0.013A) (Table 1). 218 
However, the mean SAP was higher in DKM compared to DAM (p = 0.025A) (Table 1). 219 
Although rescue analgesia with fentanyl was necessary for three cats (14%) in DKM 220 
and none in DAM, these proportions were not significant between groups (p = 0.20F).  221 
 222 
Postoperative pain assessment and quality of recovery assessment 223 
Rescue analgesia with buprenorphine was administered to 9 cats in group DAM and to 224 
8 cats in group DKM (p = 0.76F) (Table 2). There was no difference between groups in 225 
postoperative pain UNESP-Botucatu MCPS  (p = 0.20) or VAS scores (p = 0.63) at T0, 226 
T1, T2 and T3. Repeated measures ANOVA showed an increase pain score from active 227 
interaction to 1 hour, after which all pain scores decreased over time in both groups 228 
(UNESP-Botucatu MCPS (p = 0.078) and VAS (p = 0.07), see Table 2).  229 
Rescue sedation was administered to four cats in DKM and no cats in DAM (p = 230 
0.107F). Time from IM atipamezole injection to active interaction was 4 (0-28) minutes 231 
for DAM and 6 (0-50) minutes for DKM (p = 0.22MW). For recovery, SDS scores were 232 
better in the DAM group (p = 0.002MW), see Table 2. 233 
 234 
Discussion 235 
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In the present study, both IM protocols showed comfortable and reliable recoveries for 236 
ovariectomies. The duration of these teaching-surgeries (72 ± 15 minutes) required 237 
multiple supplemental doses that are unlikely to be necessary in a shorter general 238 
practice ovariohysterectomy (21 ± 7 minutes, Case et al. 2015).  239 
In our study, both groups were administered a drug mixture containing 240 
dexemedetomidine and methadone. After IM injection, no adverse effects such as 241 
excitement-dissociation or vomiting were observed. Alpha-2 and µ receptors are found 242 
in similar anatomical regions (i.e. in the brain and spinal cord) and they have common 243 
signal transduction pathways (G proteins) and mechanisms of action, such as activation 244 
of potassium channels in the postsynaptic neuron, making the cell insensitive to 245 
excitatory input (Sinclair 2003). This association can provoke synergistic effects if used 246 
simultaneously (Ossipov et al. 1990) and could be at the origin of the excitement-free 247 
recoveries. 248 
Contrarily to some publications where dexmedetomidine administered alone 249 
provoked some emesis (McSweeney et al. 2012; Nagore et al. 2013), no animal 250 
presented with these symptoms in this study. It is possible that combination with 251 
methadone, which has antiemetic effects (Robertson & Taylor 2004) at sedating doses, 252 
blocked the emetic action of dexmedetomidine (Blancquaert et al. 1986). Also, the 253 
recent study of Papastefanou et al. (2015) demonstrated that administration of 254 
dexmedetomidine and butorphanol together prevented emesis and reduced the incidence 255 
and severity of nausea compared with dexmedetomidine alone.  256 
The time to the first supplemental dose was shorter in the DKM group compared 257 
to the DAM group. This observation is in contrast to the pharmacokinetics of ketamine 258 
and alfaxalone, where the former has a longer half-life compared to the latter in cats 259 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
(Whittem et al. 2008). The dilution of ketamine, performed to adjust the DKM solution 260 
to an equal injectable volume as the DAM solution, could have affected the 261 
redistribution kinetics of ketamine and subsequently the need for an earlier 262 
supplemental dose. In addition, palpebral reflex was maintained constantly in the DKM 263 
group, unlike the DAM group and could have affected the anaesthetist’s perception of 264 
the deep plane of anaesthesia, making them more prone to administer a supplemental 265 
dose of ketamine.  266 
To maintain a plane of anaesthesia suitable for ovariectomy, it was necessary to 267 
reinject alfaxalone every 8-10 minutes following the first IV supplemental dose of 1.0 268 
mg kg-1. These results are in accordance with the Food and Drug Administration’s 269 
recommendations for alfaxalone (1.1 to 1.3 mg kg-1 every 7-8 minutes, NADA, 2012). 270 
In our study, the total alfaxalone dose used for the maintenance of anaesthesia was 0.23 271 
(0.10-0.35) mg kg-1 minute-1. In the study of Schwarz et al. (2014), total intravenous 272 
anaesthesia (TIVA) with alfaxalone after premedication with medetomidine and 273 
butorphanol was 0.17 ± 0.02 mg kg-1 minute-1 IV. This difference in effective alfaxalone 274 
dose might be because of the different routes of administration (intermittent doses 275 
versus TIVA) rather than an over-estimation of the anaesthesia requirements in our 276 
study. Supplemental doses may require a larger total dose of drug compared with TIVA 277 
to maintain a similar plane of anaesthesia. In addition, the extended duration of our 278 
teaching-ovariectomies could have influenced the anaesthetic requirements. 279 
Intraoperative rescue analgesia was indirectly used to estimate the absence or 280 
presence of nociception. Both combination groups were equivalent for intraoperative 281 
analgesia requirements. As ketamine has analgesic effects, in contrast to the 282 
questionable clinical analgesic effects of alfaxalone, we were expecting an analgesic 283 
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superiority in the DKM group. We believe the analgesic equivalence of both groups is 284 
likely the result of the addition of methadone and dexmedetomidine to both protocols. 285 
Their strong analgesic properties could have masked differences between the DKM and 286 
DAM groups. Moreover, the doses of dexmedetomidine and methadone used produce 287 
bradycardia that could have masked tachycardia resulting from pain, and produced 288 
profound sedation that could have masked blinking and movement resulting from pain. 289 
In order to minimize this possible confounding factor, our physiological baseline values 290 
(HR, fR and SAP), were determined after the dexmedetomidine and methadone 291 
administration at the moment of induction and before any surgical stimulation. 292 
Overall intraoperative respiratory rate was significantly lower in DKM 293 
compared with DAM, but no difference was seen in arterial oxygen saturation (SpO2). 294 
Even though DKM showed a lower respiratory rate, it did not cause respiratory 295 
depression. Respiratory depression has been reported with the use of ketamine alone or 296 
in combination with an alpha-2 agonist (e.g. medetomidine; Harrison et al. 2011). 297 
Likewise, alfaxalone has been also associated, during intravenous induction, with a 298 
dose-dependent decrease in respiratory rate and minute volume (Whittem et al. 2008; 299 
Beths et al. 2014). However, Grubb et al. (2013) showed no respiratory decrease when 300 
alfaxalone was administered intramuscularly to cats, which is in accordance with the 301 
results of our study. It is our opinion that the decreased respiratory rate might result 302 
from the 1 mg kg-1 dose of IV alfaxalone administered during anaesthesia. This dose is 303 
close to alfaxalone’s inducation dose. This remains to be investigated. 304 
The DKM group had higher systolic blood pressure compared with the DAM 305 
group, but there were no differences in HR between the two groups. The similar heart 306 
rates in both groups likely results from the bradycardic effect of dexmedetomidine plus 307 
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methadone. The higher SAP in the DKM group is expected because of the greater 308 
cardiac sympathetic action of ketamine (Peck et al. 2008). Unfortunately, the scientific 309 
literature is incomplete concerning the sympathetic effects of alfaxalone and therefore 310 
we cannot compare the mechanism on systolic blood pressure. 311 
To evaluate postoperative pain, we used a VAS because it has been widely 312 
employed in veterinary research for its ease, rapidity reliability and general assessment 313 
of trends (Mich & Hellyer 2009). Nonetheless, VAS can be subjective and moderately 314 
imprecise (Mich & Hellyer 2009). As we used a dissociative drug (ketamine), the ideal 315 
cut-off point was modified, because of the residual dissociation interference to 40 mm. 316 
Moreover, the VAS is not a very precise way to define an “ideal” pain score. To 317 
overcome these limitations, we opted for the parallel use of a multidimensional 318 
composite UNESP-Botucatu MCPS validated for the cat. This combination of two pain 319 
scales offered the best compromise of ease, speed, reliability and objectivity. We did 320 
not see any significant difference between groups for postoperative pain assessments. 321 
Recently, in a similar study comparing post ovariectomy pain in cats after alfaxalone-322 
alone or ketamine-medetomidine anaesthesia, Kalchofner-Guerrero et al. (2014) 323 
reported that anaesthesia with ketamine-medetomidine provided better post-surgical 324 
analgesia than alfaxalone alone, but in this study opioids where not used during the 325 
surgical procedure. Probably, our pain scales were not sensitive enough to detect slight 326 
differences in analgesia between the two groups because the combination of 327 
dexmedetomidine plus methadone was efficacious enough to prevent any analgesic 328 
difference, if any, being revealed between ketamine and alfaxalone. 329 
Ketamine has also been associated with a confounding effect on the 330 
psychomotor subscale of the UNESP-Botucatu MCPS (Buisman et al. 2015). In our 331 
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attempt to reduce this interference, we assessed pain after an active interaction with 332 
each animal, while in the study of Buisman et al. (2015) pain scale evaluations were 333 
performed hourly post-extubation. Similar postoperative pain studies in cats after 334 
ovariectomy have included meloxicam administration before (Benito-de-la-Víbora et al. 335 
2008) or at completion of surgery to assure postoperative analgesia. To avoid 336 
interference with the pain score assessments we administered meloxicam, only at the 337 
end of the study. 338 
We did not observe any statistical difference between groups in recovery values, 339 
which were overall of good quality. Dysphoric recoveries are well documented with 340 
ketamine (Baggot 1976) but have also been reported after administration of alfaxalone 341 
(Zaki et al. 2009; Grubb et al. 2013; Rodrigo-Mocholi D et al. 2015).  In the DAM 342 
group none of the cats required rescue sedation compared to four animals in the DKM 343 
group. This is probably because of the faster pharmacokinetics of alfaxalone (Whittem 344 
et al. 2008), and the use of atipamezol to reverse the sedative effects produced by 345 
dexmedetomidine. Further investigation is necessary to understand the mechanism of 346 
alfaxalone emergence reactions. 347 
Additionally, there were others limitations to this study. First, the large volume 348 
of the anaesthetic agents required for IM injection (after equivalency between groups) 349 
necessitated administering the drugs into two injections. These lumbar IM injections 350 
increased the level of pain and stress. Second, we have included all animals that were 351 
administered rescue analgesia and sedation in the final statistics study. This could have 352 
lead to bias in the results. Third, learning students performed the ovariectomies, so time 353 
of surgery was prolonged. Consequently, multiple additional doses were required. If the 354 
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study were transposed to clinical practice supplemental doses would unlikely be 355 
necessary, making it a simple protocol. 356 
 357 
Conclusion and clinical relevance 358 
In this randomized prospective clinical trial, both anaesthesia protocols were suitable 359 
for cats undergoing ovariectomy and were comparable in quality of anaesthesia and 360 
analgesia. When combined with methadone and dexmedetomidine, alfaxalone and 361 
ketamine showed comfortable and reliable recoveries. 362 
 363 
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Tables 478 
Table 1 Data after injection of intramuscular (IM) dexmedetomidine (15 µg kg-1), 479 
methadone (0.3 mg kg-1) and alfaxalone (3 mg kg-1)(DAM, n=22) or dexmedetomidine 480 
(15 µg kg-1), methadone (0.3 mg kg-1) and ketamine (3 mg kg-1) (DKM, n=22) to cats 481 
undergoing ovarioectomy. Cardiorespiratory measurements were taken every 5 minutes 482 
during surgery. The number of supplemental doses were the number administered after 483 
the first supplemental dose (1 mg kg-1 of either alfaxalone or ketamine). 484 
 Group  
Parameter DAM DKM p-value 
Time to sternal recumbency (minutes) 1 ± 1 2 ± 1 N/A 
Time to lateral recumbency (minutes) 2 ± 1 4 ± 2 N/A 
Time to first supplemental dose (minutes) 58 ± 18 47 ± 16 0.046* 
Number of supplemental doses (n°) 4 (1-6) 3 (1-7) 0.44 
HR (beats minute-1) 128 ± 29 138 ± 21 0.23 
SpO2 (%) 94 ± 3 94 ± 1 0.26 
fR (breaths minute-1) 30 ± 7 25 ± 6 0.013* 
SAP (mmHg) 125 ± 16 141 ± 27 0.025* 
*Statistically significant between groups.  Data are reported as mean ± standard 485 
deviation or median (range). 486 
N/A, non-applicable; HR, heart rate; SpO2, haemoglobin oxygen saturation; fR, 487 
respiratory rate; SAP, systolic arterial pressure 488 
  489 
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Table 2 Medians and percentiles [10th – 90th] of  recovery quality, assessed with a 490 
simple descriptive scale (SDS) and postoperative pain assessed with a Visual Analogue 491 
Scale (VAS)  and the UNESP-Botucatu multidimensional composite pain scale (MCPS) 492 
and recorded from 43 cats undergoing elective ovariectomy. Pain assessments were 493 
carried out at various time points: as soon as the cats were observed to interact actively 494 
with the investigator (T0), and then 1 (T1), 2 (T2) and 3 (T3) hours after that.  495 
 496 
 Group 
Parameter DAM (n=21) DKM (n=22) 
Recovery score 0 (0-1) 1(0-3) 
VAS T0 40 (0-60) 20 (0-58) 
VAS T1 20 (0-60) 40 (0-78) 
VAS T2 20 (0-60) 20 (0-58) 
VAS T3 0 (0-40) 20 (0-40) 
MCPS T0 2 (0-5) 1 (1-6) 
MCPS T1 1 (0-13) 2 (0-10) 
MCPS T2 1 (0-5) 1(0-8) 
MCPS T3 0 (0-4) 1 (0-7) 
The SDS ranged from 0) very smooth recovery to 3) very poor recovery; the VAS 497 
ranged from 0) no pain to 100) worst possible pain and the MCPS ranged from 0) no 498 
pain to 24) worst possible pain. 499 
 500 
DAM, dexemedetomidine, methadone and alfaxalone; DKM (dexemedetomidine, 501 
methadone and ketamine.   502 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
Figure 1 Consort Flow Diagram 503 
 504 
Assessed for eligibility (n= 49) 
Excluded  (n= 5) 
♦   Not meeting inclusion criteria (n= 5) 
 
Analysed  (n= 21) 
♦ Excluded from analysis (n= 1)  
Post-operative pain and quality of recovery 
assessment. Discharge of the patient before 
the end of the study. 
Allocated to intervention DAM (n= 22) 
♦ Received allocated intervention (n= 22)  
♦ Did not receive allocated (n= 0) 
Allocated to intervention DKM (n= 22) 
♦ Received allocated intervention (n= 22) 
♦ Did not receive allocated intervention (n= 0) 
Analysed  (n= 22) 
♦ Excluded from analysis (n= 0) 
 
Allocation 
Analysis 
Randomized (n=44) 
Enrollment 
